Agenus Management
Management criteria checks 2/4
Agenus' CEO is Garo Armen, appointed in Jan 1994, has a tenure of 30.25 years. total yearly compensation is $5.86M, comprised of 12.1% salary and 87.9% bonuses, including company stock and options. directly owns 0.58% of the company’s shares, worth $607.42K. The average tenure of the management team and the board of directors is 2.3 years and 5.4 years respectively.
Key information
Garo Armen
Chief executive officer
US$5.9m
Total compensation
| CEO salary percentage | 12.1% |
| CEO tenure | 30.3yrs |
| CEO ownership | 0.6% |
| Management average tenure | 2.3yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet
Mar 29
Agenus: 2024 May Finally Be The Year For A Major Turnaround
Jan 18Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet
Dec 22News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts
Nov 09A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)
Oct 04Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts
May 10VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma
Oct 12Agenus New Trials Set It Up For The Long Haul
Sep 27Agenus: It's Always Tomorrow
Sep 16Agenus GAAP EPS of -$0.17, revenue of $20.93M
Aug 09Agenus: Successfully Pulled Itself Away From Disaster
Jul 04Agenus: Not Quite Enough
Apr 19Auditors Have Doubts About Agenus (NASDAQ:AGEN)
Mar 06Agenus: Making Another Effort With The FDA
Jan 25Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains
Aug 25Agenus Multiple Value-Adding Events Ahead
Aug 18Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts
Aug 11FDA accepts Agenus' balstilimab BLA under "priority review" status
Jun 17Agenus/Bristol-Myers Squibb Deal Makes For A Strong Buy
May 26Agenus shares fall after Q1 topline miss
May 06Is Agenus Inc. (NASDAQ:AGEN) Popular Amongst Institutions?
Feb 15CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$6m | US$710k | -US$246m |
| Sep 30 2023 | n/a | n/a | -US$271m |
| Jun 30 2023 | n/a | n/a | -US$263m |
| Mar 31 2023 | n/a | n/a | -US$240m |
| Dec 31 2022 | US$6m | US$689k | -US$220m |
| Sep 30 2022 | n/a | n/a | -US$215m |
| Jun 30 2022 | n/a | n/a | US$18m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$10m | US$655k | -US$24m |
| Sep 30 2021 | n/a | n/a | US$4m |
| Jun 30 2021 | n/a | n/a | -US$226m |
| Mar 31 2021 | n/a | n/a | -US$190m |
| Dec 31 2020 | US$6m | US$677k | -US$181m |
| Sep 30 2020 | n/a | n/a | -US$174m |
| Jun 30 2020 | n/a | n/a | -US$168m |
| Mar 31 2020 | n/a | n/a | -US$171m |
| Dec 31 2019 | US$10m | US$634k | -US$108m |
| Sep 30 2019 | n/a | n/a | -US$126m |
| Jun 30 2019 | n/a | n/a | -US$113m |
| Mar 31 2019 | n/a | n/a | -US$87m |
| Dec 31 2018 | US$3m | US$610k | -US$160m |
| Sep 30 2018 | n/a | n/a | -US$147m |
| Jun 30 2018 | n/a | n/a | -US$151m |
| Mar 31 2018 | n/a | n/a | -US$158m |
| Dec 31 2017 | US$4m | US$593k | -US$121m |
Compensation vs Market: Garo's total compensation ($USD5.86M) is above average for companies of similar size in the US market ($USD681.24K).
Compensation vs Earnings: Garo's compensation has increased whilst the company is unprofitable.
CEO
Garo Armen (70 yo)
30.3yrs
Tenure
US$5,856,319
Compensation
Dr. Garo H. Armen, Ph.D. founded Agenus Inc. in 1994 and has been Chief Executive Officer since 1994. He serves as an Executive Chairman at MiNK Therapeutics, Inc. Dr. Armen serves as an Executive Chairman...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 30.3yrs | US$5.86m | 0.58% $ 607.4k | |
| VP of Finance | 17.5yrs | US$712.75k | 0.037% $ 38.3k | |
| Chief Medical Officer | 3.3yrs | US$1.44m | 0.065% $ 67.7k | |
| Chief Information Officer | 2.3yrs | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Chief People Officer | 2.3yrs | no data | no data | |
| Scientific Director & Head of Drug Discovery | no data | no data | no data | |
| Chief Manufacturing Officer | no data | no data | no data | |
| Chief Quality Officer | 2.3yrs | no data | no data | |
| Member of Advisory Board & Chief Strategic Advisor | less than a year | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data | |
| Chief Medical Affairs Officer | less than a year | no data | no data |
2.3yrs
Average Tenure
62yo
Average Age
Experienced Management: AGEN's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 25.3yrs | US$5.86m | 0.58% $ 607.4k | |
| Member of Advisory Board & Chief Strategic Advisor | 1.3yrs | no data | no data | |
| Member of Advisory Board | 1.3yrs | US$1.04m | no data | |
| Independent Director | 7.9yrs | US$366.39k | 0.030% $ 30.8k | |
| Independent Lead Director | 17.3yrs | US$385.50k | 0.013% $ 13.8k | |
| Member of Advisory Board | 1.3yrs | no data | no data | |
| Independent Director | 17.1yrs | US$888.14k | 0.022% $ 22.9k | |
| Independent Director | 3.5yrs | US$242.00k | 0.028% $ 29.5k | |
| Independent Director | 5.4yrs | US$242.00k | 0.016% $ 16.4k |
5.4yrs
Average Tenure
67yo
Average Age
Experienced Board: AGEN's board of directors are considered experienced (5.4 years average tenure).